email article
Patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) had slower rates of decline in lung function over 1 year when treated with nintedanib (Ofev), an intracellular inhibitor of tyrosine kinases, according to a post-hoc analysis from a larger trial known as INBUILD.
Among patients with RA-ILD randomized to nintedanib, the rate of decline in forced vital capacity (FVC) at 52 weeks was -82.6 mL/year compared with a rate of -199.3 mL/year among those receiving placebo, which represented a difference of 116.7 mL/year (95% CI 7.4-226.1,
P=0.037), reported Clive Kelly, MD, of Newcastle University in Newcastle upon Tyne in England, at the European League Against Rheumatism virtual congress.
Nintedanib Slows Interstitial Lung Disease in Patients With RA medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.